CROSS-FILE MATRIX
Compare the evidence, not the labels
Four peptides organized by target, model, endpoint, and the question each evidence base can actually answer.
In plain English
These four compounds do not belong on one efficacy ranking. They act on different systems and are studied for different outcomes. CJC-1295 is an endocrine signal tested mainly through growth hormone and IGF-1 measurements. Retatrutide is a metabolic triple agonist with randomized Phase 2 outcomes in weight, liver fat, and type 2 diabetes. GHK-Cu is a copper-binding tripeptide with broad laboratory research and smaller topical skin and hair studies. Thymosin alpha-1 is an immune modulator with decades of clinical research and a large recent sepsis trial that found no survival benefit.
A useful comparison therefore asks four questions: What is the target? What was the study model? What endpoint was measured? How mature is the evidence? Matching those fields prevents a cell experiment from being compared directly with a human trial and prevents a biomarker change from being treated as a clinical outcome. The table is a map of study structure, not a scorecard or treatment guide.
The cross-file evidence matrix
| File | Main target or role | Strongest model in this corpus | Main measured signal | Responsible reading |
|---|---|---|---|---|
| CJC-1295 | GHRH receptor and downstream GH/IGF-1 axis | Small human pharmacology studies | Sustained hormone changes with pulsatility preserved [4][5] | Biological activity is established; long-term clinical benefit is not |
| Retatrutide | GIP, GLP-1, and glucagon receptors | Randomized Phase 2 human trials | Body weight, liver fat, and HbA1c changes [10][11][12] | Large intermediate-stage effects; approval and long-term outcomes remain unresolved |
| GHK-Cu | Copper delivery, matrix signaling, broad gene-expression pathways | Reviews, small topical human studies, ex vivo skin | Procollagen response, hair counts, penetration, gene-expression patterns [13][14][15][17] | Formulation and route limit translation; systemic claims are unsupported |
| Thymosin alpha-1 | Dendritic cells, Toll-like receptors, and T-cell regulation | Large multicenter Phase 3 sepsis trial | No significant difference in short-term mortality [18] | Strong null evidence narrows earlier positive interpretations |
Mechanism: precise receptor maps versus broad pathway stories
CJC-1295 and retatrutide have comparatively clear receptor-level maps. CJC-1295 activates the GHRH receptor, then the downstream GH/IGF-1 axis [1]. Retatrutide forms active complexes with three named metabolic receptors, confirmed by structural and signaling work [9]. That precision helps define the experiment, though it does not guarantee clinical benefit.
GHK-Cu has a broader proposed network: copper transport, matrix remodeling, antioxidant effects, and large transcriptomic shifts [14][16]. Breadth increases the number of plausible outcomes but also the distance between mechanism and confirmed human effect. Thymosin alpha-1 lies between these patterns. It has defined immune-cell and Toll-like receptor pathways, yet immune effects depend heavily on disease state and co-therapy [21]. A mechanistic diagram is a rationale for testing, not a clinical endpoint.
Evidence maturity: size, control, and endpoint
Retatrutide’s Phase 2 program includes randomized human outcomes and substantial measured effects [10][11][12]. Its main limitation is maturity: pivotal and long-term outcomes are not represented in the supplied corpus. CJC-1295’s human work is older and smaller, focused on pharmacokinetics, hormones, and serum markers [3][4][5]. Those studies answer whether the axis moves, not whether health outcomes improve.
GHK-Cu’s corpus combines reviews, topical studies, a combination hair trial, and ex vivo skin penetration [13][15][17]. It is the easiest file in which to overgeneralize from laboratory breadth. Thymosin alpha-1 has the most instructive evidence sequence. A smaller randomized study suggested a mortality difference of uncertain significance [22]; a later Phase 3 trial in more than one thousand patients found virtually no difference [18]. Stronger design and scale deserve more weight than narrative momentum.
Cautions: what differs by file
For CJC-1295, the central cautions are investigational status, prolonged GH/IGF-1 stimulation, and confusion between DAC and no-DAC forms [4][7]. For retatrutide, controlled trials document gastrointestinal adverse events and heart-rate change, while the broader long-term outcome program is incomplete [11][12]. For GHK-Cu, route and formulation dominate: topical evidence does not validate injection, and delivery through intact skin is limited [13][17]. For thymosin alpha-1, immune context matters, US non-approval remains relevant, and the large null sepsis result argues against assumed benefit [18][19].
Across all four, unverified research-market material introduces product identity and quality questions that clinical trials do not answer. Anecdotal reports may suggest questions for study, but they cannot resolve those concerns. The comparison ends where the literature ends.
A reusable reading template
A compact note for any peptide paper can use six fields:
- Identity: exact molecule, variant, and formulation.
- Question: mechanism, biomarker, symptoms, or clinical outcome.
- Design: cells, animals, observational humans, or randomized trial.
- Population and time: who or what was studied, and for how long.
- Finding: effect size, comparator, uncertainty, and adverse events.
- Boundary: what the paper cannot establish.
Applied consistently, the template prevents the common slide from “receptor activation” to “proven benefit.” It also keeps null results visible. Each compound page on this desk follows the same progression, making differences in the evidence base easier to inspect.